Management of Primary Sclerosing Cholangitis
Adults with confirmed PSC require lifelong multidisciplinary follow-up with no routine medical therapy recommended, focusing instead on surveillance for complications, symptom management, and timely liver transplantation referral. 1
Medical Therapy
Do not use ursodeoxycholic acid (UDCA) for routine treatment of PSC. 1 The evidence is clear with strong recommendations against UDCA for both disease treatment and prevention of colorectal cancer or cholangiocarcinoma. This represents a departure from older practices and reflects high-quality evidence showing lack of benefit.
Do not use corticosteroids or immunosuppressants for classic PSC. 1 These agents are contraindicated unless the patient has overlap features with autoimmune hepatitis or IgG4-related sclerosing cholangitis, in which case corticosteroids may be indicated.
Disease Monitoring
Baseline Assessment
- Screen all PSC patients for inflammatory bowel disease using colonoscopy with colonic biopsies 1, as up to 88% have associated IBD 2
- Assess for cirrhosis and portal hypertension to determine need for variceal screening
- Evaluate for osteoporosis in all patients 1
- Check for fat-soluble vitamin deficiency (A, D, E, K), particularly in advanced disease 1
Ongoing Surveillance
Perform endoscopic variceal screening per international guidelines when cirrhosis or portal hypertension is present. 1 This follows standard cirrhosis surveillance protocols.
Conduct annual (or biennial if complete remission) colonoscopic surveillance for IBD 3, with heightened attention to:
- Infectious colitis risk
- Mycophenolate-related colitis
- Colorectal cancer surveillance (PSC-IBD carries significantly increased colorectal cancer risk) 4, 2
Do not routinely measure CA19-9 for cholangiocarcinoma surveillance 1, as it has low diagnostic accuracy despite potentially supporting diagnosis when cholangiocarcinoma is already suspected clinically.
Management of New or Changing Symptoms
When patients develop new symptoms, changing symptoms, or evolving laboratory abnormalities, perform non-invasive imaging with MRCP, dynamic liver MRI, and/or contrast CT. 1 This approach prioritizes safety while maintaining diagnostic accuracy.
Do not proceed directly to ERCP—require expert multidisciplinary assessment first to justify endoscopic intervention. 1 This critical recommendation prevents unnecessary procedural risks.
When ERCP is Indicated
If multidisciplinary review determines ERCP is necessary for dominant strictures:
- Administer prophylactic antibiotics 1
- Perform pathological sampling of all suspicious strictures (mandatory) 1 to exclude cholangiocarcinoma
- Prefer biliary balloon dilatation over stent insertion 1
Suspected Cholangiocarcinoma
When cholangiocarcinoma is clinically suspected, immediately refer for specialist multidisciplinary meeting review. 1 Initial investigation should be contrast-enhanced cross-sectional imaging (CT or MRI). Tissue diagnosis requires histology obtained through ERCP-guided sampling (brush cytology, FISH, endobiliary biopsy, cholangioscopy), EUS-guided biopsy, or percutaneous biopsy as determined by MDM. 1
Symptom Management
Pruritus
- First-line: cholestyramine or similar bile acid sequestrants 1
- Second-line: rifampicin or naltrexone 1
Fatigue
Actively investigate and treat alternative causes of fatigue 1 rather than attributing it solely to PSC.
Nutritional Support
Maintain low threshold for empirical fat-soluble vitamin replacement in advanced PSC 1, as deficiency is common and replacement is safe.
Care Coordination
Patients with early, stable disease can be managed in general hepatology clinics, but those with symptomatic, evolving, or complex disease require expert multidisciplinary assessment. 1 This risk-stratified approach optimizes resource utilization while ensuring appropriate specialist input.
Refer eligible patients to centers participating in clinical trials 1, as no approved therapy currently exists and novel agents are under investigation.
Liver Transplantation
PSC is a well-recognized indication for liver transplantation—assess eligibility and refer according to national guidelines. 1 Typical indications include:
- End-stage liver disease with decompensation
- Recurrent bacterial cholangitis
- Intractable pruritus
- Hepatocellular carcinoma within criteria
Post-Transplant Considerations
Recurrent PSC (rPSC) occurs in 20-30% of patients 3, with diagnosis based on Graziadei criteria requiring:
- Confirmed PSC pre-transplant
- Biliary stricturing on cholangiography >90 days post-transplant
- Compatible histology
- Exclusion of hepatic artery thrombosis/stenosis, ductopenic rejection, and anastomotic strictures alone
Continue IBD surveillance post-transplant with annual or biennial colonoscopy 3, as approximately one-third experience IBD exacerbation after transplantation. Optimal IBD control post-transplant may reduce rPSC risk, though evidence is evolving.
Critical Pitfalls to Avoid
- Never use UDCA routinely—strong evidence shows no benefit
- Never perform ERCP without prior multidisciplinary review—prevents unnecessary procedural complications
- Never assume fatigue is solely PSC-related—investigate alternative causes
- Never delay transplant referral—PSC has unpredictable progression and serious complications
- Never discontinue IBD surveillance post-transplant—cancer risk persists and IBD activity may affect graft outcomes